D-PHARM REPORTS RESULTS OF EPILEPSY STUDY

D-Pharm has reported clinical results obtained with DP-VPA, the company's proprietary lipid modified version of valproic acid (VPA). DP-VPA was well-tolerated in patients with resistant epilepsy and had a marked effect on reducing seizure frequency.

In the Phase II double-blind, placebo-controlled crossover study, DP-VPA was tested as add-on therapy for the treatment of complex partial seizures. Analysis of the first period of the study, which lasted 28 days, showed a significant reduction in seizure frequency relative to placebo with no significant adverse events.